help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mahler, D. A.
Right arrow Articles by Shah, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mahler, D. A.
Right arrow Articles by Shah, T.
American Journal of Respiratory and Critical Care Medicine Vol 166. pp. 1084-1091, (2002)
© 2002 American Thoracic Society

Articles

Effectiveness of Fluticasone Propionate and Salmeterol Combination Delivered via the Diskus Device in the Treatment of Chronic Obstructive Pulmonary Disease

Donald A. Mahler, Patrick Wire, Donald Horstman, Chai-Ni Chang, Julie Yates, Tracy Fischer and Tushar Shah

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire; and GlaxoSmithKline, Research Triangle Park, North Carolina

Correspondence and requests for reprints should be addressed to to Donald A. Mahler, M.D., Dartmouth Hitchcock Medical Center, Section of Pulmonary and Critical Care Medicine, 1 Medical Center Drive, Lebanon, NH 03756–0001. E-mail: donald.a.mahler{at}hitchcock.org

ABSTRACT

This randomized controlled trial examined the benefits of combining an inhaled corticosteroid, fluticasone propionate (F), with an inhaled long-acting ß2-agonist, salmeterol (S), to treat the inflammatory and bronchoconstrictive components of chronic obstructive pulmonary disease (COPD). A total of 691 patients with COPD received the combination of F and S (FSC), S (50 mcg), F (500 mcg), or placebo twice daily via the Diskus device for 24 weeks. A significantly greater increase in predose FEV1 at the endpoint was observed after FSC (156 ml) compared with S (107 ml, p = 0.012) and placebo (-4 ml, p < 0.0001). A significantly greater increase in 2-hour postdose FEV1 at the endpoint was observed after treatment with FSC (261 ml) compared with F (138 ml, p < 0.001) and placebo (28 ml, p < 0.001). There were greater improvements in the Transition Dyspnea Index with FSC (2.1) compared with F (1.3, p = 0.033), S (0.9, p < 0.001), and placebo (0.4, p < 0.0001). The incidence of adverse effects (except for an increase in oral candidiasis with FSC and F) was similar among the treatment groups. We conclude that FSC improved lung function and reduced the severity of dyspnea compared with individual components and placebo.

Key Words: chronic obstructive pulmonary disease • ß2-agonist • inhaled corticosteroid • Transition Dyspnea Index




This article has been cited by other articles:


Home page
 ChestHome page
R. Agarwal, A. N. Aggarwal, D. Gupta, and S. K. Jindal
Inhaled Corticosteroids vs Placebo for Preventing COPD Exacerbations: A Systematic Review and Metaregression of Randomized Controlled Trials
Chest, February 1, 2010; 137(2): 318 - 325.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. T. Ferguson, P. M. A. Calverley, J. A. Anderson, C. R. Jenkins, P. W. Jones, L. R. Willits, J. C. Yates, J. Vestbo, and B. Celli
Prevalence and Progression of Osteoporosis in Patients With COPD: Results From the Towards a Revolution in COPD Health Study
Chest, December 1, 2009; 136(6): 1456 - 1465.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. J. Rodrigo, J. A. Castro-Rodriguez, and V. Plaza
Safety and Efficacy of Combined Long-Acting {beta}-Agonists and Inhaled Corticosteroids vs Long-Acting {beta}-Agonists Monotherapy for Stable COPD: A Systematic Review
Chest, October 1, 2009; 136(4): 1029 - 1038.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Suissa and P. J. Barnes
Inhaled corticosteroids in COPD: the case against
Eur. Respir. J., July 1, 2009; 34(1): 13 - 16.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
S. Singh, A. V. Amin, and Y. K. Loke
Long-term Use of Inhaled Corticosteroids and the Risk of Pneumonia in Chronic Obstructive Pulmonary Disease: A Meta-analysis
Arch Intern Med, February 9, 2009; 169(3): 219 - 229.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
M Najafzadeh, C A Marra, M Sadatsafavi, S D Aaron, S D Sullivan, K L Vandemheen, P W Jones, and J M Fitzgerald
Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD
Thorax, November 1, 2008; 63(11): 962 - 967.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
A. Tronde, M. Gillen, L. Borgstrom, J. Lotvall, and J. Ankerst
Pharmacokinetics of Budesonide and Formoterol Administered Via 1 Pressurized Metered-Dose Inhaler in Patients With Asthma and COPD
J. Clin. Pharmacol., November 1, 2008; 48(11): 1300 - 1308.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
K. F. Rabe, W. Timmer, A. Sagkriotis, and K. Viel
Comparison of a Combination of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Moderate COPD
Chest, August 1, 2008; 134(2): 255 - 262.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
O. N. Keene, P. M. A. Calverley, P. W. Jones, J. Vestbo, and J. A. Anderson
Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited
Eur. Respir. J., July 1, 2008; 32(1): 17 - 24.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
D Singh, J Brooks, G Hagan, A Cahn, and B J O'Connor
Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD
Thorax, July 1, 2008; 63(7): 592 - 598.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
J. A. Falk, O. A. Minai, and Z. Mosenifar
Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, May 1, 2008; 5(4): 506 - 512.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. J. Rodrigo, L. J. Nannini, and R. Rodriguez-Roisin
Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review
Chest, May 1, 2008; 133(5): 1079 - 1087.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Med.Home page
C. McDonald
Review: long-acting inhaled therapies and pulmonary rehabilitation are effective in stable COPD
Evid. Based Med., April 1, 2008; 13(2): 56 - 56.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al.
Outcomes for COPD pharmacological trials: from lung function to biomarkers
Eur. Respir. J., February 1, 2008; 31(2): 416 - 469.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S D Aaron, D Fergusson, G B Marks, S Suissa, K L Vandemheen, S Doucette, F Maltais, J F Bourbeau, R S Goldstein, M Balter, et al.
Counting, analysing and reporting exacerbations of COPD in randomised controlled trials
Thorax, February 1, 2008; 63(2): 122 - 128.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. Briggs, M. Spencer, H. Wang, D. Mannino, and D. D. Sin
Development and Validation of a Prognostic Index for Health Outcomes in Chronic Obstructive Pulmonary Disease
Arch Intern Med, January 14, 2008; 168(1): 71 - 79.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J.-P. Zheng, L. Yang, Y. M. Wu, P. Chen, Z. G. Wen, W.-J. Huang, Y. Shi, C.-Z. Wang, S.-G. Huang, T.-y. Sun, et al.
The Efficacy and Safety of Combination Salmeterol (50 {micro}g)/Fluticasone Propionate (500 {micro}g) Inhalation Twice Daily Via Accuhaler in Chinese Patients With COPD
Chest, December 1, 2007; 132(6): 1756 - 1763.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
A. Qaseem, V. Snow, P. Shekelle, K. Sherif, T. J. Wilt, S. Weinberger, D. K. Owens, and for the Clinical Efficacy Assessment Subcommittee
Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians
Ann Intern Med, November 6, 2007; 147(9): 633 - 638.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
T. J. Wilt, D. Niewoehner, R. MacDonald, and R. L. Kane
Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline
Ann Intern Med, November 6, 2007; 147(9): 639 - 653.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Bourbeau, G. Ford, H. Zackon, N. Pinsky, J. Lee, and G. Ruberto
Impact on patients' health status following early identification of a COPD exacerbation
Eur. Respir. J., November 1, 2007; 30(5): 907 - 913.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
N. Barnes
Reducing inflammation in COPD: the evidence builds
Thorax, November 1, 2007; 62(11): 927 - 928.
[Full Text] [PDF]

Home page
 ThoraxHome page
J. Bourbeau, P. Christodoulopoulos, F. Maltais, Y. Yamauchi, R. Olivenstein, and Q. Hamid
Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial
Thorax, November 1, 2007; 62(11): 938 - 943.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
N. A. Hanania and J. F. Donohue
Pharmacologic Interventions in Chronic Obstructive Pulmonary Disease: Bronchodilators
Proceedings of the ATS, October 1, 2007; 4(7): 526 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
S. Suissa, R. McGhan, D. Niewoehner, and B. Make
Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, October 1, 2007; 4(7): 535 - 542.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. F. Rabe, S. Hurd, A. Anzueto, P. J. Barnes, S. A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. van Weel, et al.
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary
Am. J. Respir. Crit. Care Med., September 15, 2007; 176(6): 532 - 555.
[Abstract] [Full Text] [PDF]

Home page
 J Intensive Care MedHome page
J. Chang and Z. Mosenifar
Differentiating COPD From Asthma in Clinical Practice
J Intensive Care Med, September 1, 2007; 22(5): 300 - 309.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
S. D. Aaron, K. L. Vandemheen, D. Fergusson, F. Maltais, J. Bourbeau, R. Goldstein, M. Balter, D. O'Donnell, A. McIvor, S. Sharma, et al.
Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial
Ann Intern Med, April 17, 2007; 146(8): 545 - 555.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. Parimon, J. W. Chien, C. L. Bryson, M. B. McDonell, E. M. Udris, and D. H. Au
Inhaled Corticosteroids and Risk of Lung Cancer among Patients with Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., April 1, 2007; 175(7): 712 - 719.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. M.A. Calverley, J. A. Anderson, B. Celli, G. T. Ferguson, C. Jenkins, P. W. Jones, J. C. Yates, J. Vestbo, and the TORCH investigators
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
N. Engl. J. Med., February 22, 2007; 356(8): 775 - 789.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. E. Niewoehner and T. J. Wilt
Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease: A Status Report
Am. J. Respir. Crit. Care Med., January 15, 2007; 175(2): 103 - 104.
[Full Text] [PDF]

Home page
 ERRHome page
D. E. O'Donnell
Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance
Eur. Respir. Rev., December 1, 2006; 15(99): 37 - 41.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
M. Decramer
Tiotropium as essential maintenance therapy in COPD
Eur. Respir. Rev., December 1, 2006; 15(99): 51 - 57.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. E. O'Donnell, F. Sciurba, B. Celli, D. A. Mahler, K. A. Webb, C. J. Kalberg, and K. Knobil
Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD.
Chest, September 1, 2006; 130(3): 647 - 656.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
D. A. Mahler
Mechanisms and Measurement of Dyspnea in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, May 1, 2006; 3(3): 234 - 238.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
K. F. Rabe
Improving Dyspnea in Chronic Obstructive Pulmonary Disease: Optimal Treatment Strategies
Proceedings of the ATS, May 1, 2006; 3(3): 270 - 275.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R. Leigh, M. M. M. Pizzichini, M. M. Morris, F. Maltais, F. E. Hargreave, and E. Pizzichini
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment
Eur. Respir. J., May 1, 2006; 27(5): 964 - 971.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S Scott, P Walker, and P M A Calverley
COPD exacerbations {middle dot} 4: Prevention
Thorax, May 1, 2006; 61(5): 440 - 447.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
N. C. Barnes, Y.-S. Qiu, I. D. Pavord, D. Parker, P. A. Davis, J. Zhu, M. Johnson, N. C. Thomson, P. K. Jeffery, and on behalf of the SCO30005 Study Group
Antiinflammatory Effects of Salmeterol/Fluticasone Propionate in Chronic Obstructive Lung Disease
Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 736 - 743.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
J. F. Donohue
Combination Therapy for Chronic Obstructive Pulmonary Disease: Clinical Aspects
Proceedings of the ATS, November 1, 2005; 2(4): 272 - 281.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. Juan, M. Ramon, J. C. Valia, J. Cortijo, E. Rubio, E. Morcillo, and P. Calverley
Palliative Treatment of Dyspnea With Epidural Methadone in Advanced Emphysema
Chest, November 1, 2005; 128(5): 3322 - 3328.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. A. van Noord, J-L. Aumann, E. Janssens, J. J. Smeets, J. Verhaert, B. Disse, A. Mueller, and P. J. G. Cornelissen
Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
Eur. Respir. J., August 1, 2005; 26(2): 214 - 222.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
E. F. Hansen and J. Vestbo
Bronchodilator reversibility in COPD: the roguish but harmless little brother of airway hyperresponsiveness?
Eur. Respir. J., July 1, 2005; 26(1): 6 - 7.
[Full Text] [PDF]

Home page
 ThoraxHome page
E F M Wouters, D S Postma, B Fokkens, W C J Hop, J Prins, A F Kuipers, H R Pasma, C A J Hensing, E C Creutzberg, and for the COSMIC (COPD and Seretide: a Multi-Center
Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial
Thorax, June 1, 2005; 60(6): 480 - 487.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
C B Cooper and D P Tashkin
Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease
BMJ, March 19, 2005; 330(7492): 640 - 644.
[Full Text] [PDF]

Home page
 ThoraxHome page
C E Brightling, S McKenna, B Hargadon, S Birring, R Green, R Siva, M Berry, D Parker, W Monteiro, I D Pavord, et al.
Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease
Thorax, March 1, 2005; 60(3): 193 - 198.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. D. Scanlon, J. E. Connett, R. A. Wise, D. P. Tashkin, T. Madhok, M. Skeans, P. C. Carpenter, W. C. Bailey, A. S. Buist, M. Eichenhorn, et al.
Loss of Bone Density with Inhaled Triamcinolone in Lung Health Study II
Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1302 - 1309.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
J. F. Donohue and J. A. Ohar
Effects of Corticosteroids on Lung Function in Asthma and Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, November 1, 2004; 1(3): 152 - 160.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
P. W. Jones
Clinical Effects of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, November 1, 2004; 1(3): 167 - 170.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. P. Tashkin, H. E. Murray, M. Skeans, R. P. Murray, and for the Lung Health Study Research Group
Skin Manifestations of Inhaled Corticosteroids in COPD Patients: Results From Lung Health Study II
Chest, October 1, 2004; 126(4): 1123 - 1133.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. A. Mahler, S. Huang, M. Tabrizi, and G. M. Bell
Efficacy and Safety of a Monoclonal Antibody Recognizing Interleukin-8 in COPD: A Pilot Study
Chest, September 1, 2004; 126(3): 926 - 934.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
The TORCH Study Group
The TORCH (TOwards a Revolution in COPD Health) survival study protocol
Eur. Respir. J., August 1, 2004; 24(2): 206 - 210.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. A. El-Kassimi and N. A. Hanania
Differentiating Asthma and COPD Patients
Chest, August 1, 2004; 126(2): 653 - 655.
[Full Text] [PDF]

Home page
 ChestHome page
J. F. Donohue
Therapeutic Responses in Asthma and COPD: Bronchodilators
Chest, August 1, 2004; 126(2_suppl_1): 125S - 137S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. W. Mapel
Treatment Implications on Morbidity and Mortality in COPD
Chest, August 1, 2004; 126(2_suppl_1): 150S - 158S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Cazzola and R. Dahl
Inhaled Combination Therapy With Long-Acting {beta}2-Agonists and Corticosteroids in Stable COPD
Chest, July 1, 2004; 126(1): 220 - 237.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P.N.R. Dekhuijzen
Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease
Eur. Respir. J., April 1, 2004; 23(4): 629 - 636.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
Are Seretide and Symbicort useful in COPD?
DTB, March 1, 2004; 42(3): 18 - 21.
[Abstract] [Full Text] [PDF]

Home page
 Chronic Respiratory DiseaseHome page
P M Meek
Measurement of dyspnea in chronic obstructive pulmonary disease: what is the tool telling you?
Chronic Respiratory Disease, January 1, 2004; 1(1): 29 - 37.
[Abstract] [PDF]

Home page
 ChestHome page
D. P. Tashkin and C. B. Cooper
The Role of Long-Acting Bronchodilators in the Management of Stable COPD
Chest, January 1, 2004; 125(1): 249 - 259.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. D. Sin, F. A. McAlister, S. F. P. Man, and N. R. Anthonisen
Contemporary Management of Chronic Obstructive Pulmonary Disease: Scientific Review
JAMA, November 5, 2003; 290(17): 2301 - 2312.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
N. A. Hanania, P. Darken, D. Horstman, C. Reisner, B. Lee, S. Davis, and T. Shah
The Efficacy and Safety of Fluticasone Propionate (250 {micro}g)/Salmeterol (50 {micro}g) Combined in the Diskus Inhaler for the Treatment of COPD
Chest, September 1, 2003; 124(3): 834 - 843.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
The pharmacoepidemiology of COPD: Recent advances and methodological discussion
Eur. Respir. J., September 1, 2003; 22(43_suppl): 1s - 44s.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2002
Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 356 - 370.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2002 American Thoracic Society 		  Membership Renewal